Skip to main content
. 2024 Oct 28;10:454. doi: 10.1038/s41420-024-02220-y

Fig. 1. c-Met knockdown inhibits malignant phenotypes in osimertinib-resistant NSCLC cell lines.

Fig. 1

A MTS analysis of cell viability of HCC827/HCC827OR and H1975/H1975OR cells treated with osimertinib for 72 h. B Soft agar clone formation assay to analyze the colony-forming ability of HCC827/HCC827OR and H1975/H1975OR cells after 24 h of treatment with osimertinib. Scale bar, 200 μm. ns indicates no statistical significance. ***P < 0.001. C Immunoblotting assay to detect the protein expression level of c-Met in NSCLC parental and drug-resistant cells. Stable cell lines of HCC827OR and H1975OR knocked down with c-Met were constructed, and the protein expression level of c-Met was analyzed by WB (D), cell viability was analyzed by MTS cell viability assay (E), and the soft agar clone formation assay colony forming ability was analyzed (F). Scale bar, 200 μm. ***P < 0.001. Xenograft tumor models were analyzed for the effect of c-Met knockdown on HCC827OR tumor volume (G), tumor mass (H), tumor weight (I), Ki67 expression level (J), and mouse survival (K). Scale bar, 25 μm. ***P < 0.001.